Paula G Heller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5664088/publications.pdf

Version: 2024-02-01

63 papers	2,606 citations	218677 26 h-index	189892 50 g-index
65 all docs	65 docs citations	65 times ranked	2964 citing authors

#	Article	IF	Citations
1	Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nature Genetics, 2015, 47, 535-538.	21.4	274
2	Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history ofMYH9-related disease. Human Mutation, 2008, 29, 409-417.	2.5	172
3	MYH9-Related Disease: A Novel Prognostic Model to Predict the Clinical Evolution of the Disease Based on Genotype-Phenotype Correlations. Human Mutation, 2014, 35, 236-247.	2.5	154
4	ANKRD26-related thrombocytopenia and myeloid malignancies. Blood, 2013, 122, 1987-1989.	1.4	145
5	Spectrum of the Mutations in Bernard-Soulier Syndrome. Human Mutation, 2014, 35, 1033-1045.	2.5	124
6	Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. Blood, 2014, 124, e4-e10.	1.4	112
7	Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. Blood, 2012, 120, 2708-2718.	1.4	93
8	Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. Haematologica, 2017, 102, 1192-1203.	3.5	92
9	Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. Blood, 2005, 105, 4664-4670.	1.4	91
10	Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. Leukemia, 2016, 30, 999-1002.	7.2	86
11	Heavy chain myosin 9-related disease (MYH9-RD): Neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thrombosis and Haemostasis, 2010, 103, 826-832.	3.4	81
12	RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM). Seminars in Hematology, 2017, 54, 75-80.	3.4	79
13	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	3.8	64
14	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. Haematologica, 2014, 99, 1387-1394.	3.5	63
15	Pulmonary Hypertension in Paroxysmal Nocturnal Hemoglobinuria. Chest, 1992, 102, 642-643.	0.8	62
16	Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms. Scientific Reports, 2016, 6, 38738.	3.3	60
17	JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. European Journal of Haematology, 2006, 77, 210-216.	2.2	58
18	Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targets. Journal of Thrombosis and Haemostasis, 2014, 12, 761-772.	3.8	55

#	Article	IF	Citations
19	Correlation between platelet phenotype and NBEAL2 genotype in patients with congenital thrombocytopenia and Â-granule deficiency. Haematologica, 2013, 98, 868-874.	3.5	49
20	Platelet Apoptosis in Adult Immune Thrombocytopenia: Insights into the Mechanism of Damage Triggered by Auto-Antibodies. PLoS ONE, 2016, 11, e0160563.	2.5	47
21	Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms. Frontiers in Immunology, 2019, 10, 1373.	4.8	43
22	Moyamoya Syndrome in an Adolescent With Essential Thrombocythemia. Stroke, 2005, 36, E71-3.	2.0	39
23	Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count. British Journal of Haematology, 2014, 165, 854-864.	2.5	39
24	The clinical course of patients with septic abortion admitted to an intensive care unit. Intensive Care Medicine, 2004, 30, 1097-1102.	8.2	34
25	Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia. Scientific Reports, 2019, 9, 2208.	3.3	30
26	Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia. Frontiers in Immunology, 2020, 11, 705.	4.8	29
27	Megakaryocytic emperipolesis and platelet function abnormalities in five patients with gray platelet syndrome. Platelets, 2015, 26, 751-757.	2.3	28
28	Anagrelide plateletâ€lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms. Journal of Thrombosis and Haemostasis, 2015, 13, 631-642.	3.8	27
29	MYH9-related disease: Five novel mutations expanding the spectrum of causative mutations and confirming genotype/phenotype correlations. European Journal of Medical Genetics, 2013, 56, 7-12.	1.3	26
30	Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease. Ear and Hearing, 2016, 37, 112-120.	2.1	24
31	Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patients. Scientific Reports, 2016, 6, 23213.	3.3	24
32	Production of functional platelet-like particles by the megakaryoblastic DAMI cell line provides a model for platelet biogenesis. Platelets, 2011, 22, 26-36.	2.3	22
33	International collaboration as a tool for diagnosis of patients with inherited thrombocytopenia in the setting of a developing country. Journal of Thrombosis and Haemostasis, 2012, 10, 1653-1661.	3.8	22
34	Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel. Blood Advances, 2021, 5, 414-431.	5.2	19
35	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	3.8	19
36	Dysregulation of stromal derived factor 1/CXCR4 axis in the megakaryocytic lineage in essential thrombocythemia. British Journal of Haematology, 2009, 144, 69-77.	2.5	18

#	Article	IF	Citations
37	Unexplained recurrent venous thrombosis in a patient withMYH9-related disease. Platelets, 2006, 17, 274-275.	2.3	17
38	Primary myelofibrosis in a patient who developed primary biliary cirrhosis, autoimmune hemolytic anemia and fibrillary glomerulonephritis. Annals of Hematology, 2008, 87, 1019-1020.	1.8	16
39	Downregulation of TREM-like transcript-1 and collagen receptor Î±2 subunit, two novel RUNX1-targets, contributes to platelet dysfunction in familial platelet disorder with predisposition to acute myelogenous leukemia. Haematologica, 2019, 104, 1244-1255.	3.5	16
40	Mutations of RUNX1 in families with inherited thrombocytopenia. American Journal of Hematology, 2017, 92, E86-E88.	4.1	15
41	Longâ€term followâ€up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to <scp>JAK</scp>2/<scp>CALR</scp>/<scp>MPL</scp> mutational status. European Journal of Haematology, 2016, 96, 435-442.	2.2	14
42	PDGF-A, PDGF-B, TGF?, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide. American Journal of Hematology, 2005, 78, 155-157.	4.1	12
43	Gray platelet syndrome: Novel mutations of the NBEAL2 gene. American Journal of Hematology, 2017, 92, E20-E22.	4.1	12
44	Monocyte IL-2RÎ± expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms. Cytokine, 2010, 51, 67-72.	3.2	11
45	BCR-ABL transcripts may be detected in essential thrombocythemia but lack clinical significance. Blood, 2001, 98, 1990-1991.	1.4	10
46	MYH9related disease: A novel missense Ala95Asp mutation of theMYH9gene. Platelets, 2009, 20, 598-602.	2.3	10
47	Autoantibodies in immune thrombocytopenia affect the physiological interaction between megakaryocytes and bone marrow extracellular matrix proteins. British Journal of Haematology, 2018, 183, 319-323.	2.5	10
48	Associated thrombophilic defects in essential thrombocythaemia: their relationship with clinical manifestations. Thrombosis Research, 2003, 112, 131-135.	1.7	8
49	Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. Haematologica, 2020, 105, 1948-1956.	3.5	7
50	Differential expression of SDF-1 receptor CXCR4 in molecularly defined forms of inherited thrombocytopenias. Platelets, 2017, 28, 602-606.	2.3	6
51	First description of revertant mosaicism in familial platelet disorder with predisposition to acute myelogenous leukemia: correlation with the clinical phenotype. Haematologica, 2020, 105, e535.	3.5	6
52	A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation. Journal of Blood Medicine, 2021, Volume 12, 719-732.	1.7	6
53	Abnormal regulation of soluble and anchored IL-6 receptor in monocytes from patients with essential thrombocythemia. Experimental Hematology, 2010, 38, 868-876.e1.	0.4	5
54	Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515Lâ€positive platelets. European Journal of Haematology, 2010, 84, 398-405.	2.2	5

#	Article	IF	Citations
55	Insertion (4;11)(q27;q24q21) in a patient with essential thrombocythemia with progression to myelofibrosis. Cancer Genetics and Cytogenetics, 2004, 154, 72-76.	1.0	3
56	Diverse Mpl expression pattern among pedigrees with inherited thrombocytopenia: potential diagnostic and therapeutic implications. Journal of Thrombosis and Haemostasis, 2008, 6, 2215-2217.	3.8	3
57	Application of a Diagnostic Algorithm for Inherited Thrombocytopenia Patients in the Setting of a Developing Country. Blood, 2011, 118, 1163-1163.	1.4	3
58	Megakaryocyteâ€“stromal cell interactions: Effect on megakaryocyte proliferation, proplatelet production, and survival. Experimental Hematology, 2022, 107, 24-37.	0.4	3
59	Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus. Platelets, 2021, , 1-12.	2.3	2
60	Platelet Apoptosis in Adult Immune Thrombocytopenia. Relationship with Auto-Antibodies, Platelet Function and Treatment. Blood, 2014, 124, 2792-2792.	1.4	1
61	Follow-Up of Clinical Manifestations and Platelet Function Test in Patients with Essential Thrombocythemia on Anagrelide Treatment.. Blood, 2005, 106, 4970-4970.	1.4	0
62	Frequency of the JAK2V617F Mutation in Platelets from Essential Thrombocythemia (ET) Patients.. Blood, 2005, 106, 4972-4972.	1.4	0
63	Real World Data on Obstetric (OC) and Maternal Complications (MC) Occurring in a Cohort of Patients with Ph Negative Myeloproliferative Neoplasms (MPN): Argentinian Multicentric Study. Blood, 2019, 134, 1669-1669.	1.4	0